4.5 Review

Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins

Journal

JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 107, Issue 5, Pages 1247-1260

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2018.01.007

Keywords

absorption; bioavailability; biotechnology; immune response; formulation; pharmacokinetics; physicochemical properties; proteins

Funding

  1. National Institutes of Health [R01 HL-70227]
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070227] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Biotherapeutics is a rapidly growing drug class, and over 200 biotherapeutics have already obtained approval, with about 50 of these being approved in 2015 and 2016 alone. Several hundred protein therapeutic products are still in the pipeline, including interesting new approaches to treatment. Owing to patients' convenience of at home administration and reduced number of hospital visits as well as the reduction in treatment costs, subcutaneous (SC) administration of biologics is of increasing interest. Although several avenues for treatment using biotherapeutics are being explored, there is still a sufficient gap in knowledge regarding the interplay of formulation conditions, immunogenicity, and pharmacokinetics (PK) of the absorption of these compounds when they are given SC. This review seeks to highlight the major concerns and important factors governing this route of administration and suggest a holistic approach for effective SC delivery. (c) 2018 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available